Coya Therapeutics, Net Worth
Coya Therapeutics, Net Worth Breakdown | COYA |
Coya Therapeutics, Net Worth Analysis
Coya Therapeutics,'s net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Coya Therapeutics,'s financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Coya Therapeutics,'s overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Coya Therapeutics,'s net worth analysis. One common approach is to calculate Coya Therapeutics,'s market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Coya Therapeutics,'s stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Coya Therapeutics,'s net worth. This approach calculates the present value of Coya Therapeutics,'s future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Coya Therapeutics,'s cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Coya Therapeutics,'s net worth. This involves comparing Coya Therapeutics,'s financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Coya Therapeutics,'s net worth relative to its peers.
Enterprise Value |
|
To determine if Coya Therapeutics, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Coya Therapeutics,'s net worth research are outlined below:
| Coya Therapeutics, had very high historical volatility over the last 90 days | |
| Coya Therapeutics, has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 3.55 B. Net Loss for the year was (14.88 B) with loss before overhead, payroll, taxes, and interest of (8.31 M). | |
| Coya Therapeutics, generates negative cash flow from operations | |
| Latest headline from finance.yahoo.com: Coya Therapeutics Is In A Good Position To Deliver On Growth Plans |
Coya Therapeutics, uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Coya Therapeutics, Common. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Coya Therapeutics,'s previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Coya Therapeutics,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 111.72 M.Market Cap |
|
Project Coya Therapeutics,'s profitablity
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.43) | (0.45) |
When accessing Coya Therapeutics,'s net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Coya Therapeutics,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Coya Therapeutics,'s profitability and make more informed investment decisions.
Please note, the presentation of Coya Therapeutics,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Coya Therapeutics,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Coya Therapeutics,'s management manipulating its earnings.
Evaluate Coya Therapeutics,'s management efficiency
Coya Therapeutics, Common has return on total asset (ROA) of (0.2515) % which means that it has lost $0.2515 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3957) %, meaning that it created substantial loss on money invested by shareholders. Coya Therapeutics,'s management efficiency ratios could be used to measure how well Coya Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. As of March 24, 2025, Return On Tangible Assets is expected to decline to -0.0004. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Coya Therapeutics,'s Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 40.5 M, whereas Net Tangible Assets are projected to grow to (14.7 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.6 K | 2.7 K | |
| Tangible Book Value Per Share | 2.6 K | 2.7 K | |
| Enterprise Value Over EBITDA | (2.84) | (2.70) | |
| Enterprise Value Multiple | (2.84) | (2.70) | |
| Enterprise Value | 49 M | 35.4 M |
The strategic vision of Coya Therapeutics, Common management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Enterprise Value Revenue 35.8048 | Revenue | Quarterly Revenue Growth (1.00) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coya Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coya Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Coya Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Coya Therapeutics, Corporate Filings
8K | 18th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 25th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 30th of January 2025 Other Reports | ViewVerify |
Coya Therapeutics, Earnings per Share Projection vs Actual
Coya Therapeutics, Corporate Management
| Arun Swaminathan | Chief Officer | Profile | |
| Howard Berman | Executive Chair | Profile | |
| Gregory MacMichael | Chief Officer | Profile | |
| Aaron Thome | Head Platform | Profile | |
| Michelle Frazier | Senior Affairs | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coya Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.98) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.